# Orthofix account plan

> Orthofix (NASDAQ: OFIX) sells spinal implants, bone growth stimulators and limb reconstruction systems; FY2025 net sales $822.3 million.

## At a glance

Orthofix Medical Inc., headquartered in Lewisville, Texas and founded in Verona, Italy in 1980, sells spinal implants, bone growth stimulation devices, biologics, limb reconstruction systems and the 7D FLASH Navigation System to hospitals, ASCs and purchasing organizations in more than 60 countries. It merged with SeaSpine in January 2023 and trades on NASDAQ as OFIX. FY2025 net sales were $822.3 million (+2.9% reported), with a gross margin of 68.8% and a net loss of $92.2 million; U.S. net sales were $684.1 million. It had 1,605 employees at the end of 2025, 1,222 of them in the U.S., and manufactures in the U.S., Canada, Germany, Spain, China and Italy. Massimo Calafiore is President and CEO.

## Business units

- **Global Spine: Therapeutic Solutions (formerly Bone Growth Therapies)** (30.0% of FY2025 net sales ($247.2 million)): PEMF and LIPUS bone growth stimulators (CervicalStim, SpinalStim, PhysioStim, AccelStim) sold almost exclusively in the U.S. through distributors and direct reps, with the STIM onTrack adherence app. Net sales grew 5.9% in 2025 and 4.5% to $64.0 million in Q3 2026; AccelStim 2.0 launched in 2026. The FDA has reclassified bone growth stimulators from Class III to Class II.
- **Global Spine: Spinal Implants, Biologics and Enabling Technologies** (53.6% of FY2025 net sales ($440.5 million)): Thoracolumbar and cervical fixation, interbodies, the VIRATA system, bone graft substitutes (some marketed for MTF Biologics) and the radiation-free 7D FLASH Navigation System, sold mainly in the U.S. through independent distributors. Sales excluding the discontinued M6 discs rose 2.8% in 2025, but Q3 2026 sales fell 1.1% to $107.4 million on supplier delays and instrument-set constraints. Global Spine as a whole was 83.6% of 2025 net sales.
- **Global Limb Reconstruction (formerly Global Orthopedics)** (16.4% of FY2025 net sales ($134.7 million)): External and internal fixation and lengthening systems (TrueLok, TL-HEX, TrueLok Elevate, Fitbone, Galaxy Fixation) and the OrthoNext planning platform, about 70% international with Verona, Italy as a historic base. Net sales grew 8.4% reported in 2025 and 8.5% to $36.4 million in Q3 2026; the company cites a $2.6 billion TAM and sees the U.S. as a greenfield opportunity.

## Strategic priorities

- **Fix U.S. Spine execution**: Concentrate on core distributors, which generate around 80% of U.S. spinal implant revenue, accelerate exits from weaker relationships and redeploy instrument sets to them.
- **Simplify the portfolio and align costs**: Focus inventory, capital and commercial support on differentiated platforms such as VIRATA, whose full market launch for open procedures is expected later in Q4 2026, after discontinuing the M6 artificial discs in February 2025.
- **Grow Limb Reconstruction in the U.S.**: Ramp TrueLok Elevate and Fitbone, pursue diabetic foot ulcers as a potential new indication (IDE submitted to the FDA) and an automated TrueLok Elevate (510(k) submitted in September 2026).
- **Integrate implants and biologics with 7D**: Move 7D FLASH from capital sales to an earn-out model tied to implant and biologics purchase commitments; earn-out placements were 30% above 2024 and 7D received two 510(k) clearances in Q3 2026.
- **Stabilize Biologics with clinical evidence**: Invest in clinical evidence for OsteoCove and a registry for OsteoStrand Plus after double-digit declines in 2025; Biologics was about flat year over year in Q2 2026.
- **Financial discipline and long-range plan**: Long-range plan targets were kept but pushed from 2027 to 2028; management targets positive free cash flow and stays open to tuck-in acquisitions.

## Latest results

In Q3 2026 (quarter ended September 30) net sales were $207.9 million, +1.1% reported and +2.2% pro forma excluding M6, with a net loss of $6.1 million and adjusted EBITDA of $26.0 million (12.5% of pro forma sales). Therapeutic Solutions grew 4.5% and Limb Reconstruction 8.5%, while Spinal Implants, Biologics and Enabling Technologies fell 1.1% and U.S. Spine Fixation fell 5%. SG&A dropped 15.4% to $125.3 million on $21.2 million lower legal costs. Over nine months net sales were $615.5 million (+2.2%) and free cash flow was $(61.3) million. Full-year 2026 guidance was cut to $825-830 million pro forma net sales and $86-88 million adjusted EBITDA.

## Investments and deals

- **Oxford Finance credit agreement**: A $275.0 million secured credit agreement: $160.0 million Initial Term Loan, $65.0 million Term B Loan drawn January 15, 2026, and a $50.0 million Term C at the lender's discretion; $225.0 million was outstanding at September 30, 2026.
- **European MDR distributor arrangement**: One of the largest European distributors is funding MDR certification for spine products, adding about $15 million of 2026 sales (mostly Q4) and creating an approximately $22 million headwind in 2027.
- **Instrument sets and capex**: Nine-month 2026 capex rose to $37.8 million from $23.7 million, including instrument sets ahead of the VIRATA launch.
- **Settlement of executive litigation**: Orthofix paid $14.8 million to its former CEO Keith Valentine in April 2026, and former executives Keran and Bostjancic settled for $4.25 million each.

## Challenges and risks

- **Supplier delays and instrument-set constraints**: Unplanned supplier delays, concentrated in instrument manufacturing and some interbody product lines, constrained inventory and instrument sets in U.S. Spine in Q3 2026.
- **Underperforming smaller distributors**: Smaller spine distributors kept underperforming, and growth among the Top 30 distributors slowed to the mid-single digits in Q3 2026.
- **Bone growth stimulator reclassification**: The FDA reclassified bone growth stimulators from Class III to Class II, which could let competitors enter more easily and lead to pricing pressure.
- **Cash generation**: Free cash flow was $(1.3) million in 2025 and $(61.3) million over the first nine months of 2026, with inventory turns down to 1.3x.
- **Pricing pressure and supplier dependence**: GPO price concessions, dependence on independent distributors and on single-source suppliers such as MTF for key allografts.

## What leadership says

> "We are concentrating resources behind our strongest partners and the highest value technology, simplifying the portfolio and aligning costs with a more focused business." — Massimo Calafiore, President and Chief Executive Officer, Q3 2026 earnings call, November 9, 2026

> "Our priorities are clear: improve U.S. Spine execution, stabilize Biologics, build on the strength of limb reconstruction, Therapeutic Solutions and maintain financial discipline." — Massimo Calafiore, President and Chief Executive Officer, Q3 2026 earnings call, November 9, 2026

> "Our objective is not growth at any cost. It is durable, profitable growth supported by better commercial productivity, disciplined investment, and stronger business fundamentals." — Massimo Calafiore, President and Chief Executive Officer, Q2 2026 earnings call, August 5, 2026

> "Over 75% of our business is with our top 30 distributors. And if you go back to 2024, that was less than 50%." — Julie Andrews, Chief Financial Officer, Canaccord Genuity Musculoskeletal Conference, March 2, 2026


## Where a supplier can help

- **Instrument and component manufacturing capacity**: Tied to the supplier-delay challenge: contract manufacturers of surgical instruments and interbody components could reduce the constraints that held back U.S. Spine.
- **Asset and inventory utilization tools**: Tied to the redeployment of instrument sets and low inventory turns: consignment tracking, set logistics and inventory analytics help core distributors turn assets faster.
- **Clinical evidence and regulatory services**: Tied to the Biologics evidence priority, the diabetic foot ulcer IDE and the European MDR work: CROs, registries and regulatory consultants.
- **U.S. commercial build-out for Limb Reconstruction**: Tied to the U.S. Limb Reconstruction priority: sales enablement, surgeon education and distributor recruitment for a market the company calls greenfield.
- **Cost alignment and cash discipline**: Tied to the cost-alignment priority and negative free cash flow: procurement, working-capital and operational efficiency services.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Orthofix Medical Inc. Annual Report on Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/884624/000119312526065189/ofix-20251231.htm)

Annual report · 2026-02-24

- Orthofix Medical Inc. is a global medical technology company headquartered in Lewisville, Texas (founded in Verona, Italy in 1980), selling spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and the 7D FLASH Navigation System; it merged with SeaSpine in January 2023 and trades on NASDAQ as OFIX.
- FY2025 net sales were $822.3 million (+2.9% reported); pro forma net sales excluding the discontinued M6 artificial discs were $811.9 million, +4.1% on a pro forma constant currency basis. Net loss was $92.2 million (11.2% of sales); gross margin 68.8%.
- Two reporting segments: Global Spine (84% of 2025 net sales: Bone Growth Therapies $247.2 million and Spinal Implants, Biologics and Enabling Technologies $440.5 million) and Global Limb Reconstruction (16%, $134.7 million, formerly "Global Orthopedics").
- The business is US-heavy: U.S. net sales $684.1 million vs. $138.2 million international; Limb Reconstruction is the international business (international $95.7 million of $134.7 million).
- Growth drivers in 2025: Global Spine Fixation +10.1%, U.S. Spine Fixation +5.5%, BGT +5.9%, U.S. Limb Reconstruction +15.8%; Biologics declined and M6 disc sales fell 55.4% after the February 2025 decision to discontinue them.
- Sells through a mix of direct reps and independent distributors to hospitals, ASCs, GPOs/IDNs in more than 60 countries; 7D FLASH is placed either as a capital sale or against long-term implant/biologics purchase commitments.
- 1,605 employees at end-2025 (1,222 in the U.S.); R&D spend $65.8 million; manufacturing in the U.S., Canada, Germany, Spain, China and Italy.
- Key risks: integration of legacy businesses, GPO pricing pressure, an FDA panel recommendation to reclassify bone growth stimulators from Class III to Class II, dependence on independent distributors and single-source suppliers (MTF for key allografts), and litigation with three former executives terminated in September 2023.
- Financing: a $275.0 million secured credit agreement with Oxford Finance; $65.0 million Term B Loan drawn on January 15, 2026; free cash flow was $(1.3) million in 2025.

### [Orthofix Medical Inc. Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/884624/000119312526452699/ofix-20260930.htm)

Interim report · 2026-11-09

- Q3 2026 (quarter to September 30, 2026) net sales were $207.9 million, +1.1% reported and +2.2% pro forma (excluding the discontinued M6 discs); net loss $6.1 million; non-GAAP adjusted EBITDA $26.0 million.
- Therapeutic Solutions (formerly Bone Growth Therapies) grew 4.5% to $64.0 million; Global Limb Reconstruction grew 8.5% (9.4% constant currency) to $36.4 million.
- Spinal Implants, Biologics and Enabling Technologies fell 1.1% to $107.4 million: growth among the Top 30 distributors slowed, held back by supplier delays and instrument-set availability, and smaller distributors kept underperforming.
- Gross margin fell to 70.5% from 72.2% on product and geography mix; SG&A dropped 15.4% to $125.3 million, mainly $21.2 million lower legal costs; operating income turned positive at 0.7% of sales.
- Nine months: net sales $615.5 million (+2.2%); free cash flow $(61.3) million as capex rose to $37.8 million and working capital absorbed cash; cash $86.9 million; $225.0 million drawn under the credit agreement.
- Litigation with the former executives is largely settled: $14.8 million paid to Valentine in April 2026, $4.25 million each to Keran and Bostjancic.
- New risk factor: the FDA reclassified bone growth stimulators from Class III to Class II, which may increase competition.

### [Orthofix Q3 2026 earnings call transcript](https://www.webull.com/news/15894929820468224)

Executive talk · Massimo Calafiore, President and Chief Executive Officer · 2026-11-09

- CEO Massimo Calafiore said Q3 2026 was "below our expectation": U.S. Spine was hurt by market softness and unplanned supplier delays that constrained inventory and instrument sets, while limb reconstruction and Therapeutic Solutions stayed strong.
- Full-year 2026 guidance was cut to $825-830 million pro forma net sales and $86-88 million adjusted EBITDA; formal 2027 guidance will come on the Q4 call.
- Recovery plan: focus on core distributors (around 80% of U.S. spinal implant revenue), exit weaker relationships, redeploy instrument sets, simplify the portfolio and align costs.
- VIRATA spinal implant system for open procedures is due for full market launch later in Q4; 7D received two 510(k) clearances in the quarter.
- CFO Julie Andrews: Q3 net sales $207.9 million (+2.3% pro forma constant currency), adjusted EBITDA $26 million (12.5% of pro forma sales); U.S. Spine Fixation -5%, Therapeutic Solutions +4%, Limb Reconstruction +9%.
- The European MDR distributor arrangement adds about $15 million of 2026 sales (mostly Q4) but creates an approximately $22 million headwind in 2027.
- Pipeline: a 510(k) was submitted for an automated TrueLok Elevate; diabetic foot ulcers are pursued as a potential new indication.

### [Orthofix Q2 2026 earnings call corrected transcript](https://s21.q4cdn.com/785927921/files/content_files/OFIX-US-CORRECTED-TRANSCRIPT-Orthofix-Medical-IncOFIXUS-Q2-2026-Earnings-Call-5August2026-830-ET-AM-04-08-2026-2026-08-04-0-2.pdf)

Executive talk · Massimo Calafiore, President and Chief Executive Officer · 2026-08-05

- CEO Massimo Calafiore called Q2 2026 "an important proof point in our transformation": 5% pro forma constant currency net sales growth, with double-digit growth in global limb reconstruction and spine fixation.
- Global Spine Fixation +10% (U.S. +3%); the Top 30 distributors are about 80% of spine fixation sales, while smaller distributors declined more steeply and are being consolidated or exited.
- CMS restored Medicare reimbursement for bone growth stimulators (an approximately $12 million benefit); Therapeutic Solutions grew 3% to $64.2 million despite the temporary cut.
- Biologics was about flat year over year after double-digit declines in 2025; the company is investing in clinical evidence for OsteoCove and a registry for OsteoStrand Plus.
- A large European distributor is funding MDR certification for spine products: about $15 million of incremental 2026 sales (mostly Q4), then about a $22 million headwind in 2027.
- Guidance raised to $845-855 million net sales and $95-98 million adjusted EBITDA (later cut in Q3); Q2 adjusted EBITDA was $20.1 million and cash $104.4 million.
- First VIRATA minimally invasive cases done; full VIRATA launch planned for Q4; an IDE was submitted to the FDA for diabetic foot ulcers.

### [Orthofix at the Canaccord Genuity Musculoskeletal Conference (CFO fireside chat)](https://s21.q4cdn.com/785927921/files/doc_events/2026/Mar/02/CORRECTED-TRANSCRIPT-Orthofix-Medical-Inc-OFIX-US-Canaccord-Genuity-Musculoskeletal-Conference-2-March-2026-10-30-AM-ET.pdf)

Executive talk · Julie Andrews, Chief Financial Officer · 2026-03-02

- CFO Julie Andrews (Canaccord Genuity Musculoskeletal Conference, March 2, 2026) said Q4 2025 "capped quarter of meaningful operational progress", with the eighth quarter of EBITDA margin expansion and strong positive free cash flow.
- Initial 2026 guidance: 5.5% pro forma growth at the midpoint, 70 bps of adjusted EBITDA margin expansion and positive free cash flow; growth about 5% in H1 and 6% in H2.
- Long-range plan targets were kept but pushed from 2027 to 2028 to capture the benefit of the 2025 Spine channel optimization.
- Over 75% of the business is now with the top 30 distributors, vs. less than 50% in 2024.
- 7D: moving from capital sales to an earn-out model; earn-out placements were 30% above 2024, and placement accounts were over 50% of their volume commitments.
- Limb Reconstruction (renamed from Orthopedics): about 70% international and 30% U.S., with a $2.6 billion TAM; U.S. Limb Recon expected to grow faster than the company for years.
- M&A: focused on running the business and free cash flow, but open to tuck-in deals now that the balance sheet is stronger.

## Questions about Orthofix

### What does Orthofix do?

Orthofix is a medical technology company in Lewisville, Texas that sells spinal implants, bone growth stimulators, biologics, limb reconstruction systems and the 7D FLASH Navigation System in more than 60 countries.

### What is Orthofix's revenue?

FY2025 net sales were $822.3 million (+2.9% reported) with a net loss of $92.2 million. For 2026 the company guides to $825-830 million of pro forma net sales.

### How many employees does Orthofix have?

1,605 employees at December 31, 2025: 1,222 in the U.S. and 383 outside, including 247 in Italy.

### Who leads Orthofix?

Massimo Calafiore is President and CEO and Julie Andrews is CFO.

### What is Orthofix's strategy?

Improve U.S. Spine execution by concentrating on core distributors, simplify the portfolio around platforms such as VIRATA and 7D, stabilize Biologics, grow Limb Reconstruction and Therapeutic Solutions, and keep financial discipline.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
